The genetics
The film deals with a real inherited disease and with how treatments for rare genetic disorders are developed and paid for. Pompe disease, or glycogen storage disease type II, is an autosomal recessive condition in which a missing enzyme, acid alpha-glucosidase, lets glycogen build up in cells and damages muscle and nerve cells throughout the body. The treatment the characters pursue is enzyme replacement therapy, which supplies the missing protein rather than correcting the gene. The scientist, Stonehill, is a gruff idealist devoted to basic research, while the companies are shown as driven by money but essential to bringing a drug to patients. A review in The Scientist found the story told with remarkable accuracy, though it noted that the sick children appear healthier than real patients and that the film tends to dismiss basic research as idealistic. The real drug, Myozyme, was approved in 2006, and enzyme replacement has greatly improved the outlook for people with Pompe disease.
The story
John Crowley, a Portland advertising executive, and his wife Aileen have two children with Pompe disease, a genetic disorder that typically kills children before their tenth birthday. John contacts Robert Stonehill, a researcher at the University of Nebraska who has done innovative work towards an enzyme treatment. To raise money for the research and the required clinical trials, John devotes himself to the cause full-time and the two found a small biotech company, which they later sell to a larger firm, Zymagen, to finance development. There, Stonehill's temper, rivalry with other research teams and the company's profit motives repeatedly threaten the project and John's hope that his own children will be treated in time. The film is based on the true story of John and Aileen Crowley, as told in the journalist Geeta Anand's book The Cure, with names and some events changed.